Antibody levels may predict COVID-19 reinfection risk
NCT ID NCT05365750
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed study followed 4,235 Kaiser Permanente Colorado members to track COVID-19 antibodies and reinfection rates over 9 months. Researchers measured antibody levels and tested for new infections to see if antibody levels could predict reinfection risk. The goal was to better understand how long immunity lasts after a first infection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help predict who is at risk for reinfection based on antibody levels.
- What could go wrong
- This is an observational study, not a treatment trial. Results may not apply to other populations or variants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kaiser Permanente
Aurora, Colorado, 80014, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?